Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus Rebif in relapsing multiple sclerosis
2010-020337-99Phase 3Unknown
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ocrelizumab arm with Interferon beta-1a (Rebif) arm (2 arms). Primary endpoint: Annualized protocol-defined relapse rate. Status: unknown.
02
Drugs
ocrelizumabinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-020337-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020337-99.